View in EDS

Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (SynflorixTM and Prevenar13TM)) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-labelled randomized controlled trial in Indian children.

Saved in:
Bibliographic Details
Title: Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (SynflorixTM and Prevenar13TM)) on nasopharyngeal carriage and serotype-specific immune response in the first two years of life: Results from an open-labelled randomized controlled trial in Indian children.
Authors: Kawade A; Vadu Rural Health Program, KEM Hospital Research Centre, Pune, India. Electronic address: anand.kawade@kemhrcvadu.org., Dayma G; Vadu Rural Health Program, KEM Hospital Research Centre, Pune, India., Apte A; Vadu Rural Health Program, KEM Hospital Research Centre, Pune, India., Telang N; Department of Microbiology, KEM Hospital, Pune, India., Satpute M; Department of Microbiology, KEM Hospital, Pune, India., Pearce E; Infection, Immunity and Inflammation Department, UCL Great Ormond Street Institute of Child Health, London, United Kingdom., Roalfe L; Infection, Immunity and Inflammation Department, UCL Great Ormond Street Institute of Child Health, London, United Kingdom., Patil R; Vadu Rural Health Program, KEM Hospital Research Centre, Pune, India., Wang Y; Infection, Immunity and Inflammation Department, UCL Great Ormond Street Institute of Child Health, London, United Kingdom., Noori N; Institute for Disease Modeling, Global Health Division, Bill and Melinda Gates Foundation, 500 5th Ave N, Seattle, WA, USA., Gondhali A; Vadu Rural Health Program, KEM Hospital Research Centre, Pune, India., Juvekar S; Vadu Rural Health Program, KEM Hospital Research Centre, Pune, India., Oron AP; Institute for Health Metrics and Evaluation, University of Washington, Seattle, USA., Sanghavi S; Department of Microbiology, KEM Hospital, Pune, India., Goldblatt D; Infection, Immunity and Inflammation Department, UCL Great Ormond Street Institute of Child Health, London, United Kingdom., Dagan R; The Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel., Bavdekar A; Vadu Rural Health Program, KEM Hospital Research Centre, Pune, India. Electronic address: a.bavdekar@kemhrcpune.org.
Source: Vaccine [Vaccine] 2023 May 05; Vol. 41 (19), pp. 3066-3079. Date of Electronic Publication: 2023 Apr 10.
Publication Type: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1873-2518
DOI:10.1016/j.vaccine.2023.04.008